Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Inclusion Criteria(Screening): * Female patients, age at diagnosis 18 - 75 years * Histological confirmed unilateral primary invasive carcinoma of the breast * Adequate surgical treatment with complete resection of the tumor (R0) and resection of \> or = 10 axillary nodes or SLN in clinically N0 patients * T1 - T4 (if operable, inflammatory breast cancer is excluded) * Her-2 non-over expressing tumor confirmed by IHC/FISH * Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to randomization. Results must be known at the time of randomization * Node positive disease or node negative disease with at least one other risk factor (tumor size \> or = 2 cm, grade \> or = 2, ER and PR negative, high uPA//PAI-1 levels) * No evidence for distant metastasis (M0) after conventional staging * Performance Status ECOG \< or = 1 or KI \> or = 80 % * The patient must be accessible for treatment and follow-up * Written informed consent for central pathology review and evaluation of Recurrence Score (HR positive) and participation in the planB trial prior to beginning specific protocol procedures HR positive patients: * Patient willingness to participate in adjuvant chemotherapy planB trial if RS \> 11 * Indication for chemotherapy given provided either \> 4 involved lymph nodes or RS \> 11 in 1-3 lymph nodes or N0 disease Additional Inclusion Criteria (Randomisation to chemotherapy): * Laboratory requirements (within 21 days prior to randomization): * Leucocytes \> or = 3.5 109/L * platelets \> or = 100 109/L * haemoglobin \> or = 10 g/dL * total bilirubin \< or = 1 ULN * ASAT (SGOT) and ALAT (SGPT) \< or = 2.5 UNL * creatinine \< 175 ymol/L (2 mg/dL) * Negative pregnancy test (urine or serum) within 7 days prior to randomization in premenopausal patients * LVEF within normal limits of each institution measured by echocardiography or MUGA scan and Exclusion Criteria(Screening): * HER2 over expression confirmed by IHC/FISH/CISH * Known hypersensitivity reaction to the compounds or incorporated substances * Known polyneuropathy \> or = grade 2 * Severe and relevant comorbidity that would interact with the application of cytotoxic agents or the participation in the study including acute cystitis and ischuria and chronic kidney disease. * Prior malignancy with a disease-free survival of \< 10 years, except curatively treated basalioma of the skin, pTis of the cervix uteri or ipsilateral ductal carcinoma in-situ (DCISpTis of the breast) * Non-operable breast cancer including inflammatory breast cancer * Previous or concurrent treatment with cytotoxic agents for any reason after consultation with the sponsor * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry * Male breast cancer * Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less then 1% failure rate) non-hormonal contraceptive measures during the study treatment * Breast feeding woman * Sequential breast cancer * Lack of patient compliance Additional Exclusion Criteria (Randomisation): * Inadequate organ function including: * Leucocytes \< 3,5 G/l * platelets \< 100 G/l * creatinine or bilirubin above normal limits * alkaline phosphatise \> 5 UNL * ASAT and/or ALAT associated with AP \> 2.5 UNL * uncompensated cardiac function * Time since axillary dissection \> 42 days